Drug Trial Radar · NCT03580655
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
107
Actual
Start
Nov 21, 2018
Primary completion
Dec 18, 2024
Study completion Dec 18, 2024
Sponsor
- Lead sponsor
- Blueprint Medicines CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jul 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL)
Conditions
- Advanced Systemic Mastocytosis
- Aggressive Systemic Mastocytosis
- Systemic Mastocytosis With an Associated Hematologic Neoplasm
- Mast Cell Leukemia
Interventions
AvapritinibDrug
Avapritinib tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) Based on Modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on Mastocytosis (mIWG-MRT-ECNM) Response CriteriaTime frame: Baseline through Month 65
Locations
32 sites in 12 countries. Site status is shown where the registry gives one.
Stanford Cancer Institute
Stanford, California
Rush University Medical Center
Chicago, Illinois
The University of Kansas Cancer Center
Westwood, Kansas
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Washington University School of Medicine
St Louis, Missouri
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Herbert Irving Comprehensive Cancer Center
New York, New York
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania
University of Texas, MD Anderson Cancer Center
Houston, Texas
Mays Cancer Center
San Antonio, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Medizinische Universität Wien, Universitätsklinik für Innere Medizin I, Klinische Abteilung für Hämatologie und Hämostaseologie
Vienna, Austria
St. Michael's Hospital
Toronto, Ontario, Canada
Odense University Hospital, Department of Haematology
Odense, Denmark
Hôpital Necker-Enfants Malades
Paris, France
CHU Toulouse - Hôpital Larrey
Toulouse, France
Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltranslplantation
Aachen, Germany
Universitätsklinikum Hamburg-Eppendorf, Zentrum für Onkologie
Hamburg, Germany
Universitätsklinikum Leipzig, Medizinische Klinik und Poliklinik I - Hämatologie und Zelltherapie, lnternistische Onkologie, Hämostaseologie
Leipzig, Germany
Universitätsmedizin Mannheim III. Medizinische Klinik
Mannheim, Germany
Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der TU München
Munich, Germany
Azienda Ospedaliero-Universitaria Careggi, CRIMM - Centro di Ricerca ed Innovazione per le Malattie Mieloproliferative
Florence, Italy
A.O. OO.RR. S.Giovanni di Dio e Ruggi d'Aragona, University of Salerno
Salerno, Italy
Centro Ricerche Cliniche di Verona - Azienda Ospedaliera Universitaria Integrata di Verona
Verona, Italy
University Medical Center Groningen (UMCG)
Groningen, Netherlands
Oslo University Hospital-Rikshospitalet, Hematology
Oslo, Norway
Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii
Gdansk, Poland
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu, Klinice Hematologii, Nowotworów Krwi i Transplantacji Szpiku
Wroclaw, Poland
lnstituto de Estudios de Mastocitosis de Castilla la Mancha, Hospital Virgen del Valle - Complejo Hospitalario de Toledo
Toledo, Spain
Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde
Glasgow, United Kingdom
Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.